Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates: focusing on personalized treatment, comorbidity management, and vaccination

doi:10.19983/j.issn.2096-8493.2024161

Abstract

Abstract:

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic airway disease characterized by persistent airflow limitation and respiratory symptoms. Given its significant heterogeneity, precise individualized treatment is of paramount importance. The 2025 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) represents a major milestone in COPD management by integrating the latest evidence-based findings and refining therapeutic strategies. The authors focuse on key updates in GOLD 2025, including personalized treatment, comorbidity management, and vaccination strategies. It aims to provide clinical COPD practitioners with insights and guidance to optimize treatment and prevention strategies, ultimately improving patients’ quality of life and long-term outcomes.

Key words: Pulmonary disease, chronic obstructive, Treatment, Disease management, Review

CLC Number:

R563.9

Jiang Qi, Ma Yiming, Chen Yan. Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates: focusing on personalized treatment, comorbidity management, and vaccination[J]. Journal of Tuberculosis and Lung Disease , 2025, 6(2): 125-127. doi: 10.19983/j.issn.2096-8493.2024161

References 21

[1]	Celli B, Fabbri L, Criner G, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. Am J Respir Crit Care Med, 2022, 206(11):1317-1325. doi:10.1164/rccm.202204-0671PP.
[2]	Agustí A, Melén E, DeMeo DL, et al. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med, 2022, 10(5):512-524. doi:10.1016/S2213-2600(21)00555-5. pmid: 35427533
[3]	Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther, 2010, 23(4):257-267. doi:10.1016/j.pupt.2010.03.003. pmid: 20381630
[4]	Ray R, Tombs L, Naya I, et al. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. Pulm Pharmacol Ther. 2019,57:101802. doi:10.1016/j.pupt.2019.101802.
[5]	Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis, 2015, 10:2207-2217. doi:10.2147/COPD.S91694..
[6]	Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J, 2020, 55(6):1900790. doi:10.1183/13993003.00351-2020.
[7]	Singh D, Lea S, Mathioudakis AG. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2021, 81(16):1821-1830. doi:10.1007/s40265-021-01616-9. pmid: 34731461
[8]	Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase Ⅲ Trials (the ENHANCE Trials). Am J Respir Crit Care Med, 2023, 208(4):406-416. doi:10.1164/rccm.202306-0944OC.
[9]	Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med, 2024, 390(24):2274-2283. doi:10.1056/NEJMoa2401304.
[10]	Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: Role of comorbidities. Eur Respir J, 2006, 28(6):1245-1257. doi:10.1183/09031936.00133805. pmid: 17138679
[11]	Fabbri LM, Celli BR, Agustí A, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med, 2023, 11(11):1020-1034. doi:10.1016/S2213-2600(23)00261-8. pmid: 37696283
[12]	Hurst JR, Gale CP. MACE in COPD: addressing cardiopulmonary risk. Lancet Respir Med, 2024, 12(5):345-348. doi:10.1016/S2213-2600(24)00038-9.
[13]	Graul EL, Nordon C, Rhodes K, et al. Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study. Am J Respir Crit Care Med, 2024, 209(8):960-972. doi:10.1164/rccm.202307-1122OC.
[14]	Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med, 2018, 198(1):51-57. doi:10.1164/rccm.201711-2239OC.
[15]	Kovacs G, Agusti A, Barberà JA, et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. Am J Respir Crit Care Med, 2018, 198(8):1000-1011. doi:10.1164/rccm.201801-0095PP.
[16]	Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic Approach. Chest, 2022, 162(1):202-212. doi:10.1016/j.chest.2022.01.031. pmid: 35092746
[17]	Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices-United States, 2024. MMWR Morb Mortal Wkly Rep,2024, 73(36):793-798. doi:10.15585/mmwr.mm7336a3.
[18]	Huang CL, Nguyen PA, Kuo PL, et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed, 2013, 111(2):507-511. doi:10.1016/j.cmpb.2013.05.006.
[19]	Wiseman DJ, Thwaites RS, Ritchie AI, et al. Respiratory Syncytial Virus-related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study. Am J Respir Crit Care Med, 2024, 210(8):994-1001. doi:10.1164/rccm.202308-1320OC.
[20]	Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices-United States, 2023. MMWR Morb Mortal Wkly Rep,2023, 72(29):793-801. doi:10.15585/mmwr.mm7229a4.
[21]	Hause AM, Moro PL, Baggs J, et al. Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine-United States, May 3, 2023-April 14, 2024. MMWR Morb Mortal Wkly Rep, 2024, 73(21):489-494. doi:10.15585/mmwr.mm7321a3.